Evogene Ltd. (NASDAQ:EVGN) Sees Large Increase in Short Interest

Evogene Ltd. (NASDAQ:EVGN) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 29,900 shares, a growth of 864.5% from the July 15th total of 3,100 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average trading volume of 16,500 shares, the short-interest ratio is currently 1.8 days.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Evogene in a report on Tuesday, August 6th. They issued a “sell” rating for the company.

Evogene Trading Down 6.7 %

Shares of NASDAQ EVGN opened at $3.88 on Tuesday. The business has a 50-day moving average of $5.86 and a 200-day moving average of $7.01. The firm has a market capitalization of $159.92 million, a price-to-earnings ratio of -8.43 and a beta of 1.40. Evogene has a 12 month low of $3.86 and a 12 month high of $10.40.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, May 23rd. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter. Evogene had a negative return on equity of 70.96% and a negative net margin of 233.66%. The company had revenue of $4.19 million during the quarter.

Hedge Funds Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets raised its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.